MedTrace Logo

The Effects of RPL554 on Top of Standard COPD Reliever Medications

NCT02542254 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-09-09

No results posted yet for this study

Summary

This study evaluates the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in a randomised sequence:

1. salbutamol,
2. ipratropium,
3. salbutamol + RPL554,
4. ipratropium + RPL554,
5. RPL554
6. Placebo

Conditions

Interventions

DRUG

Salbutamol

200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)

DRUG

Ipratropium

40 micrograms ipratropium administered using a pMDI

DRUG

RPL554

6 mg RPL554 administered using a nebuliser

DRUG

Salbutamol matched placebo

Placebo pMDI

DRUG

Ipratropium matched placebo

Placebo pMDI

DRUG

RPL554 matched placebo

Nebulised placebo

Sponsors & Collaborators

  • Verona Pharma plc

    lead INDUSTRY

Principal Investigators

  • Dave Singh · Medicines Evaluation Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02542254 on ClinicalTrials.gov